Prenetics Global (PRE) Set to Release Quarterly Earnings on Monday

Prenetics Global (NASDAQ:PRE) will likely be releasing its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Prenetics Global to announce earnings of ($0.82) per share and revenue of $63.28 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.

Prenetics Global (NASDAQ:PRE) last announced its earnings results on Wednesday, August 19th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.31. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. The business had revenue of $46.49 million during the quarter, compared to analysts’ expectations of $49.85 million. On average, analysts expect Prenetics Global to post ($1.86) EPS for the current fiscal year and ($1.15) EPS for the next fiscal year.

Prenetics Global Stock Performance

Shares of NASDAQ PRE opened at $17.76 on Monday. The stock has a 50 day moving average of $22.07 and a 200-day moving average of $19.58. The company has a market capitalization of $299.61 million, a P/E ratio of -4.27 and a beta of 0.40. Prenetics Global has a 12 month low of $11.36 and a 12 month high of $27.24.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Craig Hallum initiated coverage on shares of Prenetics Global in a report on Thursday, September 17th. They set a “buy” rating and a $40.00 price target on the stock. Benchmark increased their price target on Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Wall Street Zen upgraded shares of Prenetics Global from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. B. Riley Financial initiated coverage on shares of Prenetics Global in a research report on Thursday, August 27th. They set a “buy” rating and a $37.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a research note on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Prenetics Global has an average rating of “Moderate Buy” and an average price target of $37.17.

Insider Buying and Selling at Prenetics Global

In other news, CEO Danny Sheng Wu Yeung acquired 17,181 shares of the business’s stock in a transaction dated Monday, August 24th. The stock was bought at an average cost of $21.23 per share, for a total transaction of $364,752.63. Following the completion of the transaction, the chief executive officer owned 112,416 shares of the company’s stock, valued at $2,386,591.68. The trade was a 18.04% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Brian J. Rosin bought 5,100 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were bought at an average price of $22.80 per share, with a total value of $116,280.00. Following the completion of the transaction, the chief financial officer owned 23,100 shares of the company’s stock, valued at $526,680. The trade was a 28.33% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders bought 47,781 shares of company stock valued at $999,778.

Prenetics Global Company Profile

Prenetics Global Limited is a health sciences and genomics company founded in 2014 by Danny Yeung, who serves as its chief executive officer. Headquartered in Hong Kong, the company uses genetic sequencing, molecular diagnostics and data analysis to support consumer health, clinical care and early disease detection.

Its consumer business operates under the CircleDNA brand, which offers at-home DNA testing and reports covering areas such as wellness, nutrition, fitness, traits and genetic risk.